StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$920.69−2.65 (-0.29%)

Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –

Regeneron Pharmaceuticals Total Research and Development (R&D) Expenses by Quarter

Total Research and Development (R&D) Expenses ($M) ($M)

Regeneron Pharmaceuticals Total Research and Development (R&D) Expenses: $1,795M in Q3 2026, up 21.7% from a year earlier. That is the highest of the 70 quarters on record here.

Latest, Q3 2026
1,795
Period ended Sep 30, 2026
Change on a year earlier
+21.7%
1,475 in Q3 2025
History
70 quarters
Since Q2 2009
Sources
59
Documents cited below

Where the Q3 2026 figure comes from

“R&D Expenses Table (FY2026Q3): Total research and development expenses | $ | 1,794.7 | $ | 1,475.0 | $ | 319.7 | $ | 4,969.8 | $ | 4,224.1 | $ | 745.7”

Source: Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗

Reported in Form 10-Q / 10-K Consolidated Statements of Operations & MD&A R&D Table.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal Research and Development (R&D) Expenses ($M) ($M)Year on yearSource
Q3 2026Sep 30, 20261,795+21.7%Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Q2 2026Jun 30, 20261,632+14.8%Form 10-Q (regn-20260630.htm, filed 2026-07-30) ↗
Q1 2026Mar 31, 20261,544+16.3%Form 10-Q (regn-20260331.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 20251,626+15.2%Form 10-K (regn-20251231.htm; 0000872589-26-000034|regn-20260930.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 20251,475+16.0%Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Q2 2025Jun 30, 20251,422+18.5%Form 10-Q (regn-20260630.htm, filed 2026-07-30) ↗
Q1 2025Mar 31, 20251,327+6.3%Form 10-Q (regn-20260331.htm, filed 2026-04-29) ↗
Q4 2024Dec 31, 20241,412+20.0%Form 10-K (regn-20251231.htm; 0000872589-25-000028|regn-20250930.htm, filed 2026-02-04) ↗
Q3 2024Sep 30, 20241,272+18.2%Form 10-Q (regn-20250930.htm, filed 2025-10-28) ↗
Q2 2024Jun 30, 20241,200+10.6%Form 10-Q (regn-20250630.htm, filed 2025-08-01) ↗
Q1 2024Mar 31, 20241,248+13.4%Form 10-Q (regn-20250331.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 20231,177+12.9%Form 10-K (regn-20251231.htm; 0001804220-24-000040|regn-20240930.htm, filed 2026-02-04) ↗
Q3 2023Sep 30, 20231,075+18.0%Form 10-Q (regn-20240930.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 20231,085+36.6%Form 10-Q (regn-20240630.htm, filed 2024-08-01) ↗
Q1 2023Mar 31, 20231,101+30.5%Form 10-Q (regn-20240331.htm, filed 2024-05-02) ↗
Q4 2022Dec 31, 20221,043+41.4%Form 10-K (regn-20241231.htm; 0001804220-23-000031|regn-20230930.htm, filed 2025-02-05) ↗

Breakdown

What makes up total Research and Development (R&D) Expenses

Cite this data

StockData. (2026). Regeneron Pharmaceuticals Total Research and Development (R&D) Expenses ($M), quarterly Q2 2009–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-tot

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?